• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: Imatinib mesylate
Trade Name: Gleevec
Date Designated: 08/25/2005
Orphan Designation: Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia
Orphan Designation Status: Designated/Approved
Novartis Pharmaceuticals Corporation
One Health Plaza
Mail Code 105/1E870D
East Hanover, New Jersey 07936
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: Imatinib mesylate
Trade Name: Gleevec
Marketing Approval Date: 10/19/2006
Approved Labeled Indication: Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRÿ}ÿ± fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRÿ}ÿ± fusion kinase negative or unknown
Exclusivity End Date: 10/19/2013 
Exclusivity Protected Indication* :  

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.